Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at .WALTHAM, Mass., Nov. 25, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that will participate in a fireside chat and investor meetings at the 7th Annual Evercore ISI HealthCONx Conference. Details of the fireside are as follows:
马萨诸塞州沃尔瑟姆，2024年11月25日 /PRNewswire/ -- Spyre Therapeutics, Inc. (纳斯达克: SYRE) 是一家临床阶段的生物技术公司，利用一流的抗体工程、合理的治疗组合和精准医疗方法，旨在提高治疗炎症性肠病（"IBD"）的疗效和便利性，今天宣布将参加第七届evercore ISI HealthCONx会议的炉边聊天和投资者会议。炉边聊天的详细信息如下：
- Tuesday, December 3, 2024, at 7:30 a.m. Eastern time
- 2024年12月3日，东部时间上午7:30
To access this webcast, please visit the "Events & Presentations" page within the Investors section of the Spyre website at ir.spyre.com. An archive of the webcast will be available for replay following the end of the conference.
要访问此网络直播，请访问Spyre网站投资者部分的"活动与演示"页面，网址为ir.spyre.com。会议结束后，将提供网络直播的档案以供重播。
About Spyre Therapeutics
关于Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at .
Spyre Therapeutics是一家临床阶段的生物技术公司，旨在通过结合最先进的抗体工程、合理的治疗组合和精密的医学方法，创建下一代炎症性肠病（IBD）产品。Spyre的产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体。了解更多信息，请访问Spyre的网站。
Follow Spyre Therapeutics on social media: @spyretx and LinkedIn
在社交媒体上关注Spyre Therapeutics: @spyretx和LinkedIn
SOURCE Spyre Therapeutics, Inc.
资料来源：Spyre Therapeutics, Inc.
